John Allinson, is a Fellow of the
Institute of Biomedical Sciences (FIBMS)
and, having spent 22 years in diagnostic
laboratories in the National Health
Service, has experience in all major
fields of clinical pathology. He has
managed and developed specialist laboratory
services for drug monitoring, trace
metals, and immunoassays. During a
tenure in a large CRO, he developed
analytical services for a large central
clinical laboratory conducting all
phases of pre-clinical and clinical
trials. This work necessitated the
validation of more than 100 immunoassays
on a variety of analytical platforms.
In 2001-2005 John led the development
of new analytical services including
the biomarkers laboratory as Laboratory
Director of BASI UK.
John is a respected speaker at a number
of conferences internationally, addressing
the topic of biomarkers, regulatory
issues, and the synergies with traditional
bioanalytical laboratories. He is
a member of the Biomarker Committee
of the AAPS Ligand Binding Assay Bioanalytical
Focus Group (LBABFG) whose aims are
to produce recommendations for the
industry for biomarker assays and
their validation – the first
white paper being published in the
AAPS journal -Pharmaceutical Research-
in February 2006.
|
